-

Gold Standard Diagnostics COVID-19 Antibody Tests Now Available

DAVIS, Calif.--(BUSINESS WIRE)--The Gold Standard Diagnostics Group (GSD) including Gold Standard Diagnostics Inc., VIROTECH Diagnostics GmbH, and NovaTec Immundiagnostica GmbH today announced the immediate availability of three different serological assays for detection of antibodies against the novel coronavirus SARS-CoV-2. GSD followed the FDA’s Emergency Use Notification process as provided in the FDA’s Policy for Diagnostic Tests for Coronavirus Disease-2019 during the Public Health Emergency (March 16, 2020). These kits are now available worldwide.

The IgA, IgG, and IgM assays are formatted for optimal functionality in diagnostic laboratories each with a total incubation time of 90 minutes at room temperature with ready to use controls. The kits are designed to be run manually and on any open automated EIA platform. Several hundred samples were run in development studies including PCR confirmed patients, cross-reactive samples, and convalescent sample draws.

According to experts, there is a large range of applications for serologic testing. As knowledge develops about the immunity to potential reinfection of patients having previously contracted COVID-19 and recovered, antibodies testing may provide information about statistically reduced contagion risks of and from these persons. Therefore, reliable detection of these antibodies will play an important role in combating the disease and preventing the spread of infections. GSD’s COVID-19 serology assays are designed to help patients and doctors and will be a valuable tool for epidemiological studies.

Working with talented scientists who always put the patient first, and never compromise on quality has allowed Gold Standard Diagnostics to fast track high quality antibody assays to support global COVID-19 testing efforts. The ability to support antibody testing should increase our understanding of the disease and support health authorities in protecting the health of the population.

For more information on these kits and GSD’s other products used in the effort to prevent the spread of COVID-19 please contact your local GSD representative, email USSales@gsdx.us, or www.gsdx.us.

ABOUT GOLD STANDARD DIAGNOSTICS, GROUP

Gold Standard Diagnostics, Group is a clinical diagnostics group comprised of Gold Standard Diagnostics Inc., VIROTECH Diagnostics GmbH, and NovaTec Immundiagnostica GmbH. The companies develop, manufacture and distribute a portfolio of instrumentation and diagnostic test kits to clinical laboratories around worldwide. The US GSD Inc. is headquartered in Davis, CA. Gold Standard Diagnostics is a member of the Eurofins Technologies group of companies.

Contacts

Thomas Crowley
530-759-8000
USSales@gsdx.us

Gold Standard Diagnostics, Group


Release Versions

Contacts

Thomas Crowley
530-759-8000
USSales@gsdx.us

More News From Gold Standard Diagnostics, Group

Improved Lyme Screening Assay Now FDA Cleared for Laboratory Use

DAVIS, Calif.--(BUSINESS WIRE)--Gold Standard Diagnostics (GSD) today announced it offers a new B. burgdorferi VlsE-OspC IgG/IgM recombinant ELISA Screen that can be used to improve workflow and conserve testing resources. This assay has demonstrated increased sensitivity for early Lyme Disease detection - up to 20% over existing available Lyme screening assays - while maintaining 98% specificity. True Lyme negative samples are eliminated prior to second-tier testing. The OspC antigen used in t...

Gold Standard Diagnostics Announces FDA Clearance of the B. burgdorferi IgG/IgM VlsE-OspC EIA Test

DAVIS, Calif.--(BUSINESS WIRE)--Gold Standard Diagnostics (GSD), a Eurofins Technologies company, today announced FDA clearance of a new B. burgdorferi IgG/IgM VlsE-OspC EIA test. This test, when used in conjunction with the other FDA cleared GSD Lyme EIA tests can be used in the CDC recommended modified two-tiered testing (MTTT) algorithm. In 2014, the CDC issued an updated recommendation for the serologic diagnosis of Lyme disease, endorsing the use of a two-tier testing algorithm that uses a...

Gold Standard Diagnostics Receives FDA 510K for Lyme IgG and IgM EIA Kits

DAVIS, Calif.--(BUSINESS WIRE)--The Gold Standard Diagnostics Group (GSD) today announced the immediate availability of their two new Lyme IgG and Lyme IgM EIA kits for detection of antibodies against Lyme disease causing bacteria. The two assays give laboratories a more diverse arsenal of testing methodologies that allows them to achieve more reliable results. The assays are available immediately in the US. The separate IgG and IgM assays provide laboratories the ability to offer more specific...
Back to Newsroom